Pricing Log in Create free account
Saturday 17 October 2026 Export ILMN’s income statement to Excel — free account

Illumina, Inc.

ILMN Healthcare Diagnostics & Research

Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024. In the quarter to June 2026, revenue grew 9.44%, EPS fell 8.05%, free cash flow fell 18.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

262.03 5.90 −2.20%
Market cap
$40.5B
P/E
48.4×
Fwd P/E
34.7×
Dividend yield
—
F-score
8/9
Altman Z
4.39
Beneish M
−2.51
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Illumina, Inc. (ILMN) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Oct 13, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
8-K Aug 17, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 13, 2026 1.01 Entry into a material definitive agreement; 1.02 Termination of a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
8-K Aug 10, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 7, 2026 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 28, 2026 P1I2: no comparison — the Item was not found
P2I1A: no comparison — the Item was not found
8-K Jul 30, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jun 16, 2026 5.02 Departure or appointment of directors or officers Officer departure
8-K May 21, 2026 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits
10-Q Mar 29, 2026
8-K Apr 30, 2026 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Apr 2, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-K Dec 28, 2025 1: no comparison — the Item was not found
1A: no comparison — the Item was not found
7: no comparison — the Item was not found
8-K Feb 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 30, 2026 2.01 Completion of an acquisition or disposition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jan 13, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 8, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Nov 25, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Nov 10, 2025 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 28, 2025
8-K Oct 30, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 29, 2025
10-K Dec 29, 2024 Impairment

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.